Public, NASDAQ:SGMO
NASDAQ Global Market
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
Date: Mon, 30 Jun 2008 11:28:46 GMT
Tags:
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
PR Newswire (press release) - Jun 30, 2008
PR Newswire (press release) - Jun 30, 2008
on Form 10 - Q . Sangamo BioSciences , Inc . assumes no obligation to update the forward - looking information contained in this press release. ...
Dow licenses Sangamo technology to improve plants
Date: Wed, 18 Jun 2008 23:40:08 GMT
Tags:
Dow licenses Sangamo technology to improve plants
MSN Money - Jun 18, 2008
Dow Agrosciences Announces Exercise Of Option For Commercial License With Sangamo Biosciences - RTT News
MSN Money - Jun 18, 2008
Dow AgroSciences LLC said Wednesday it will exercise its option to license Sangamo BioSciences Inc . ' s gene manipulation technology.The deal gives Dow a tool it can use to select desirable ...
Dow AgroSciences Trademark. (PRNewsFoto/Sangamo BioSciences, Inc.) - PR Newswire (press release)Dow Agrosciences Announces Exercise Of Option For Commercial License With Sangamo Biosciences - RTT News
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date: Mon, 09 Jun 2008 15:43:28 GMT
Tags:
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
FOXBusiness - Jun 9, 2008
FOXBusiness - Jun 9, 2008
ratio.The larger group ( approximately 30 subjects ) was treated by intramuscular injection of 60 mg of SB - 509 ( 30 mg of SB - 509 per leg ) into the lower limb and will be treated every 3 ...
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date: Mon, 09 Jun 2008 00:50:24 GMT
Tags:
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
istockAnalyst.com - Jun 9, 2008
istockAnalyst.com - Jun 9, 2008
of SB - 509 per leg ) into the lower limb and will be treated every3 months.The remaining group ( approximately 15 subjects ) received an equalvolume of placebo on the same schedule.Each subject ...
Sangamo Biosciences Inc (SGMO) no change in holdings by Argyll Research Llc
Date: Sat, 07 Jun 2008 10:54:30 GMT
Tags:
Sangamo Biosciences Inc (SGMO) no change in holdings by Argyll Research Llc
Mffais.com - Jun 7, 2008
Mffais.com - Jun 7, 2008
LONG BEACH ( Mffais . com ) - Argyll Research Llc made no change in their 606,800 shares in Sangamo Biosciences Inc ( SGMO ) as shown by filings made public on 2008 - 06 - 06.The stock is currently ...
Sangamo technology shows promise in treating HIV (AP)
Date: Mon, 30 Jun 2008 13:23:33 Etc/GMT
Tags:
Sangamo BioSciences Inc., which develops genetic-based therapies, said Monday data shows the company's technology can make certain cells in the immune system resistant to the HIV virus.
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells (PR Newswire)
Date: Mon, 30 Jun 2008 11:00:00 Etc/GMT
Tags:
Sangamo BioSciences, Inc. announced today the publication of data demonstrating that human immune system cells can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN).
Guidance For Investors Discussed in Wall Street Transcript Biotechnology Report (Wall Street Transcript)
Date: Fri, 27 Jun 2008 15:34:00 Etc/GMT
Tags:
67 WALL STREET, New York - June 27, 2008 - The Wall Street Transcript has just published its Biotechnology issue, a report offering a timely review of the sector to serious investors and industry executives. This 81-page feature contains a roundtable forum and industry commentary through in depth interviews with CEOs from 13 firms and 2 analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Feuerstein's Biotech-Stock Mailbag: Delcath (at TheStreet.com)
Date: Fri, 27 Jun 2008 14:03:04 Etc/GMT
Tags:
Analysts: Sangamo's Dow deal could be key driver (AP)
Date: Thu, 19 Jun 2008 19:35:55 Etc/GMT
Tags:
Dow AgroSciences' move to license genetic-based therapies from Sangamo Biosciences Inc. could mean a large infusion of cash with little loss of product rights for the biotechnology company, according to several analysts.